REG - Oxford Biomedica PLC - OXB announces CFO transition

Oxford BioMedicaAnnouncement

17/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240717:nRSQ6661Wa&default-theme=true

RNS Number : 6661W  Oxford Biomedica PLC  17 July 2024

 

Oxford Biomedica announces Chief Financial Officer transition

- Lucinda Crabtree to join as Chief Financial Officer -

Oxford, UK - 17 July 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and
gene therapy CDMO, today announces the appointment of Lucinda (Lucy) Crabtree
Ph.D. as Chief Financial Officer (CFO) and Board member. Simultaneously, the
Company announces that Stuart Paynter will step down as CFO and from the Board
after almost seven years of service. These changes will become effective on 2
September 2024 and Stuart will then transition away from Oxford Biomedica
following a suitable handover period.

 

Lucinda Crabtree was previously CFO at MorphoSys AG. As CFO of MorphoSys, Lucy
led a finance team across the US and Germany until the closing of the
acquisition of the company by Novartis. Prior to MorphoSys, Lucy was CFO at
Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical
company. Before her time at Autolus, Lucy spent several years as an investment
professional at institutions including Woodford Investment Management, Panmure
Gordon, Goldman Sachs, J.P. Morgan (originally Bear Stearns) and Jefferies.
Lucy also has prior experience as a board observer at several private
healthcare companies. She holds a first class Bachelor of Science degree in
Physiology and Pharmacology from University College London and a Ph.D. in
Pharmacology from University College London.

 

Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: "On
behalf of the corporate executive team, I am delighted to welcome Lucy to
Oxford Biomedica. Her unique skillset will be immensely valuable to us as we
enter the next phase of our growth as a pure-play CDMO. I would also like to
warmly thank Stuart for his dedicated service to OXB. Since joining the
Company nearly seven years ago, Stuart has been instrumental in its success
right the way through to the recent transformation of our business model. We
wish him all the best for his future endeavours."

 

Stuart Paynter said: "It has been a pleasure and a privilege to help lead
Oxford Biomedica through its development to its position as a leading CDMO.
The Company is now operationally and financially in stronger health than ever
before and, with the transformation complete, it is now the natural time to
hand over to someone with Lucy's skills and experience. I look forward to
continuing to support OXB in the interim and then as it enjoys further success
and momentum in the future."

 

Lucinda Crabtree said: "This is an exciting time to join Oxford Biomedica,
having entered a new phase as an international pure-play cell and gene therapy
CDMO. I look forward to working with Frank and the senior leadership team
alongside the Board, as we continue to execute on this integrated strategy and
continue our growth in the backdrop of a rapidly expanding cell and gene
therapy market."

 

 

Relevant disclosures

 

There are no disclosures required to be made in accordance with LR 9.6.13R.

 

-Ends-

 

 

Enquiries:

 

Oxford Biomedica plc:

 

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 1865 509 737 / E:
ir@oxb.com

 

ICR Consilium:

 

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
(mailto:oxfordbiomedica@consilium-comms.com)

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract
development and manufacturing organisation (CDMO) in cell and gene therapy
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/)  and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUPCMUPCPUQ